BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 6318948)

  • 1. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan.
    Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T
    Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
    Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
    PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasopharyngeal carcinoma in Japan--clinical evaluation of EBV serology and EBV-associated nuclear antigens test.
    Takimoto T; Furukawa M; Morishita K; Umeda R; Hatano M
    Auris Nasus Larynx; 1982; 9(3):151-63. PubMed ID: 6301414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-specific serodiagnostic tests in carcinomas of the head and neck.
    Ringborg U; Henle W; Henle G; Ingimarsson S; Klein G; Silfversward C; Strander H
    Cancer; 1983 Oct; 52(7):1237-43. PubMed ID: 6309355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.
    Cevenini R; Donati M; Caliceti U; Moroni A; Tamba I; Rumpianesi F
    J Infect; 1986 Mar; 12(2):127-31. PubMed ID: 3009628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
    Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L
    J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
    Henle G; Henle W
    Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
    Shimakage M; Dezawa T; Chatani M
    Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG and IgA antibodies to Epstein-Barr virus in nasopharyngeal carcinoma patients.
    Gong SH; Lynn TC; Yang CS
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1978 Mar; 11(1):8-15. PubMed ID: 211015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.